TOKYO, Jul 03 (Pulse News Wire) – Medikit CO.,LTD. (7749.T) announced that its subsidiary, Tougo Medikit CO.,LTD., agreed to acquire all shares and subscription warrants of T.G.
Medical Co., Ltd. during a board meeting held on July 03, 2026. This acquisition aligns with MediKit's strategic plan to expand its product offerings in brain vascular treatments. T.G. Medical specializes in developing medical devices for intravascular therapy, particularly addressing arteriosclerotic thrombotic stroke, which affects approximately 15% of patients requiring mechanical thrombectomy in Japan. The company’s innovative products aim to enhance patient quality of life and simplify surgical procedures while ensuring high treatment efficacy and safety. Key details of the transaction include: - Acquisition price determined through due diligence and fair negotiations. - T.G.
Medical was established on June 17, 2020, with a capital of ¥100 million. - The deal will result in MediKit owning 100% of T.G. Medical’s equity post-acquisition. This move supports MediKit’s goal to achieve sales of up to ¥32.00 billion by March 2029, as outlined in their NEXT 300 Neo mid-term strategy. The integration of T.G. Medical complements MediKit’s existing portfolio, enhancing global expansion efforts in the field of neurovascular interventions. In addition, the agreement was finalized on July 03, 2026, with the share transfer scheduled for the same day. MediKit expects this acquisition to contribute positively to long-term growth but anticipates minimal impact on fiscal 2027 performance.
Further developments will be disclosed promptly if necessary.
🟢 Confidence: High AI-translated content.